Skip to main content
Premium Trial:

Request an Annual Quote

Incyte, Galapagos Extend Functional Genomics Deal

NEW YORK, Sept 10 – Incyte Genomics said Monday it had extended a deal with Galapagos Genomics of Mechelen, Belgium to further develop an adenoviral library for Incyte’s in-house drug development program.

Under the terms of the agreement, the companies will work to characterize the function of proteins Incyte is studying in its drug discovery and target validation programs.

The deal is an extension of a collaboration announced last year in which the companies agreed to develop and commercialize a recombinant adenoviral library for gene function discovery and validation. During the first phase of the collaboration, which included 1,500 genes from Incyte’s database, the companies tested the genes against several disease model cell lines. 

Now, Galapagos will construct a custom adenoviral library with genes relevant to Incyte's in house drug target discovery and validation efforts. Incyte will then further validate the studies using the viruses Galapagos produces.

"We are very pleased with the progress of the current collaboration," Roy Whitfield, CEO of Incyte, said in a statement.

"The Galapagos' adenoviral technology has great value for drug target validation programs and the expansion of the collaboration toward our proprietary therapeutic programs is therefore a logical extension," he added. 

Recombinant adenoviral technology is considered to be a cost-effective method that directly associates human genes with phenotypic changes such as morphology, motility, proliferation, differentiation, signal transduction, enzyme, and transport activity, Incyte said.

Financial terms of the latest deal were not disclosed.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.